デジタル投薬吸入器市場レポート：タイプ、製品、地域別、2025年～2033年

デジタル投薬吸入器の世界市場規模は2024年に38億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに118億米ドルに達し、2025年から2033年の間に12.11％の成長率（CAGR）を示すと予測しています。慢性呼吸器疾患管理への注目の高まり、リアルタイム調整のための技術進歩、喘息や慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患（CRDs）の有病率の増加は、市場を推進する主な要因の一部です。

デジタル投薬吸入器（DDI）は、喘息や慢性閉塞性肺疾患（COPD）のような呼吸器疾患に罹患している個人に薬剤を送達するために使用されます。DDIにはセンサーや電子機能が内蔵されており、投薬のタイミングや量を記録することができます。処方された治療ルーチンを確実に守り、患者の疾患と投薬の有効性をよりよく理解するのに役立ちます。ユーザーにフィードバックを提供し、テクニックを修正するのに役立つため、DDIの需要は世界中で高まっています。

現在、DDIは薬物送達における利便性と有効性の向上を提供するため、採用が増加しており、市場の成長を後押ししています。これに加えて、患者の間で効率的で効果的な吸入装置に対する需要が高まっていることも、市場の見通しを明るいものにしています。これに伴い、呼吸器系の問題を抱えやすい老年人口の間でDDIの採用が増加しており、市場の成長を後押ししています。これとは別に、DDIは治療をより透明化し、より効果的にする可能性があるため、DDIの利用が増加しており、市場の成長に寄与しています。さらに、DDIに人工知能（AI）を統合することで、薬の使用状況の監視を強化し、患者にリアルタイムのフィードバックを提供できるようになることが、市場の成長を強化しています。さらに、個人の間で個別化された医薬品への注目が高まっていることも、市場の成長を支えています。

デジタル投薬吸入器の市場動向/促進要因

慢性呼吸器疾患の有病率の増加

喘息や慢性閉塞性肺疾患（COPD）などの慢性呼吸器疾患（CRD）の有病率が世界的に上昇していることが、市場の成長に寄与しています。また、呼吸器疾患の管理を必要とする人々の間では、ドラッグデリバリーシステムの強化に対する需要が増加しています。これとは別に、DDIは正確な投与量を保証し、患者と医療提供者の両方に使用に関するフィードバックを提供することにより、最新のソリューションを提供し、これは前向きな市場展望を提供しています。これに伴い、収集されたデータは、治療計画の個別化、投薬計画のアドヒアランスの向上、CRDに関連する入院の減少に役立つ可能性があります。

リアルタイム調整のための技術の進歩

様々な企業が、より充実したケアと患者の満足度を提供するために、DDIを継続的に進化させています。各社は、ヘルスケアプロバイダーに投与量カウント、アドヒアランスモニタリング、データトランスミッションなどの機能を提供しています。これに伴い、これらの機能はより良い疾病管理を促進し、治療計画のリアルタイム調整を可能にし、患者が投薬スケジュールを効果的に遵守していることを保証するため、市場の見通しは良好です。これとは別に、DDIの技術は、治療の効果にとって重要な吸入技術に関するフィードバックを患者に即座に提供することができます。その結果、これらの進歩は、重度の呼吸器疾患を患う患者の呼吸器ケアの質を高めています。

慢性呼吸器疾患管理への注目の高まり

個人やヘルスケアプロバイダーの間で慢性呼吸器疾患（CRD）管理への注目が高まっていることが、市場の成長に寄与しています。これに伴い、CRDのより効率的かつ効果的な管理に対する需要が増加しています。これとは別に、DDIは服薬アドヒアランスを監視し、実用的なフィードバックを提供することができ、慢性呼吸器疾患管理の広範な戦略において重要な役割を果たしています。さらに、ヘルスケアプロバイダーが患者の服薬アドヒアランスと疾患の進行についてより的確な洞察を得ることができるため、タイムリーな介入が容易になり、患者の転帰が改善する可能性があります。さらに、より良い自己管理を促進するDDIの採用が増加しており、市場の成長を後押ししています。

本レポートで扱う主な質問

• 2024年の世界のデジタル投薬吸入器の市場の市場規模は？
• 2025-2033年の世界のデジタル投薬吸入器の市場の予想成長率は？
• 世界のデジタル投薬吸入器の市場を牽引する主要因は何か？
• 世界のデジタル投薬吸入器の市場に対するCOVID-19の影響は？
• 世界のデジタル投薬吸入器の市場のタイプ別内訳は？
• 世界のデジタル投薬吸入器の市場の製品別内訳は？
• 世界のデジタル投薬吸入器の市場における主要地域は？
• 世界のデジタル投薬吸入器の市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のデジタル投薬吸入器市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：タイプ別

• ブランド医薬品
  • 市場動向
  • 市場予測
• ジェネリック医薬品
  • 市場動向
  • 市場予測

第7章 市場内訳：製品別

• 定量吸入器
  • 市場動向
  • 市場予測
• ドライパウダー吸入器
  • 市場動向
  • 市場予測

第8章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋地域
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第9章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第12章 価格分析

第13章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • 3M Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • H&T Presspart Manufacturing Ltd.
  • Koninklijke Philips N.V.
  • Lupin Limited
  • Novartis AG
  • OPKO Health Inc.
  • Propeller Health（ResMed）
  • Sensirion AG Switzerland
  • Teva Pharmaceutical Industries Ltd.

List of Figures

• Figure 1: Global: Digital Dose Inhaler Market: Major Drivers and Challenges
• Figure 2: Global: Digital Dose Inhaler Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Digital Dose Inhaler Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Digital Dose Inhaler Market: Breakup by Type (in %), 2024
• Figure 5: Global: Digital Dose Inhaler Market: Breakup by Product (in %), 2024
• Figure 6: Global: Digital Dose Inhaler Market: Breakup by Region (in %), 2024
• Figure 7: Global: Digital Dose Inhaler (Branded Medication) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 8: Global: Digital Dose Inhaler (Branded Medication) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 9: Global: Digital Dose Inhaler (Generics Medication) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Global: Digital Dose Inhaler (Generics Medication) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Global: Digital Dose Inhaler (Metered Dose Inhaler) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Global: Digital Dose Inhaler (Metered Dose Inhaler) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Global: Digital Dose Inhaler (Dry Powder Inhaler) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Global: Digital Dose Inhaler (Dry Powder Inhaler) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: North America: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: North America: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: United States: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: United States: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Canada: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 20: Canada: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 21: Asia-Pacific: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 22: Asia-Pacific: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 23: China: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 24: China: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 25: Japan: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 26: Japan: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 27: India: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 28: India: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 29: South Korea: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 30: South Korea: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 31: Australia: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 32: Australia: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 33: Indonesia: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 34: Indonesia: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 35: Others: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 36: Others: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 37: Europe: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 38: Europe: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 39: Germany: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 40: Germany: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 41: France: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 42: France: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 43: United Kingdom: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 44: United Kingdom: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 45: Italy: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 46: Italy: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 47: Spain: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 48: Spain: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 49: Russia: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 50: Russia: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 51: Others: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 52: Others: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 53: Latin America: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 54: Latin America: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 55: Brazil: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 56: Brazil: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 57: Mexico: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 58: Mexico: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 59: Others: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 60: Others: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 61: Middle East and Africa: Digital Dose Inhaler Market: Sales Value (in Million USD), 2019 & 2024
• Figure 62: Middle East and Africa: Digital Dose Inhaler Market: Breakup by Country (in %), 2024
• Figure 63: Middle East and Africa: Digital Dose Inhaler Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Global: Digital Dose Inhaler Industry: SWOT Analysis
• Figure 65: Global: Digital Dose Inhaler Industry: Value Chain Analysis
• Figure 66: Global: Digital Dose Inhaler Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Digital Dose Inhaler Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Digital Dose Inhaler Market Forecast: Breakup by Type (in Million USD), 2025-2033
• Table 3: Global: Digital Dose Inhaler Market Forecast: Breakup by Product (in Million USD), 2025-2033
• Table 4: Global: Digital Dose Inhaler Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 5: Global: Digital Dose Inhaler Market: Competitive Structure
• Table 6: Global: Digital Dose Inhaler Market: Key Players

The global digital dose inhaler market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.8 Billion by 2033, exhibiting a growth rate (CAGR) of 12.11% during 2025-2033. The growing focus on chronic respiratory disease management, technological advancements for real time adjustments, and increasing prevalence of chronic respiratory diseases (CRDs), such as asthma and chronic obstructive pulmonary disease (COPD, are some of the major factors propelling the market.

A digital dose inhaler (DDI) is used for delivering medication to individuals suffering from respiratory ailments like asthma or chronic obstructive pulmonary disease (COPD). It comprises built-in sensors and electronic features that can record when the medication is administered and the quantity of the dose. It assists in ensuring adherence to prescribed treatment routines and allowing for a better understanding of the disease of the patient and the effectiveness of the medication. As it provides feedback to the users and helps them to correct their technique, the demand for DDI is rising across the globe.

At present, the increasing adoption of DDIs, as they offer enhanced convenience and effectiveness in medication delivery, is bolstering the growth of the market. Besides this, the growing demand for efficient and effective inhalation devices among patients is offering a positive market outlook. In line with this, the rising adoption of DDIs among the geriatric population, as they are more prone to respiratory issues, is propelling the market growth. Apart from this, the increasing utilization of DDIs, as they make treatment more transparent and potentially more effective, is contributing to the market growth. Furthermore, the integration of artificial intelligence (AI) in DDIs to enable enhanced monitoring of medication usage and provide real-time feedback to patients is strengthening the market growth. Moreover, the increasing focus on personalized medicines among individuals is supporting the market growth.

Digital Dose Inhaler Market Trends/Drivers:

Increasing prevalence of chronic respiratory diseases

The rising prevalence of chronic respiratory diseases (CRDs), such as asthma and chronic obstructive pulmonary disease (COPD), among the masses worldwide is contributing to the market growth. In addition, there is an increase in the demand for enhanced drug delivery systems among individuals requiring management of their respiratory conditions. Apart from this, DDIs offer a modern solution by ensuring accurate dosage and providing feedback on usage to both patients and healthcare providers, which is offering a positive market outlook. In line with this, the data collected can be instrumental in personalizing treatment plans, improving adherence to medication regimes, and potentially reducing hospitalizations related to CRDs.

Technological advancements for real time adjustments

Various companies are continuously advancing their DDIs to provide enhanced care and satisfaction to patients. They offer features, such as dose counting, adherence monitoring, and data transmission, to healthcare providers. In line with this, these features promote better disease management, allow for real-time adjustments to treatment plans, and ensure that patients are effectively adhering to their medication schedules, which is offering a favorable market outlook. Apart from this, the technology in DDIs can provide immediate feedback to patients on their inhalation technique, which is crucial for the effectiveness of the treatment. As a result, these advancements are enhancing the quality of respiratory care for patients suffering from severe respiratory disorders.

Growing focus on chronic respiratory disease management

The rising focus on chronic respiratory disease (CRD) management among individuals and healthcare providers is contributing to the growth of the market. In line with this, there is an increase in the demand for more efficient and effective management of CRDs. Apart from this, DDIs can monitor medication adherence and provide actionable feedback, which plays a crucial role in the broader strategy of chronic respiratory disease management. In addition, they enable healthcare providers to have better insights into patient adherence and disease progression, facilitating timely interventions and potentially better outcomes for patients. Furthermore, the rising adoption of DDIs, as they promote better self-management, is propelling the market growth.

Key Market Segmentation:

Breakup by Type:

Branded Medication

Generics Medication

Branded medication accounts for the majority of the market share

Breakup by Product:

Metered Dose Inhaler

Dry Powder Inhaler

Metered dose inhaler holds the largest share in the industry

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest digital dose inhaler market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the increasing adoption of advanced respiratory devices. Additionally, the presence of well-established pharmaceutical and medical device companies is offering a positive market outlook. Apart from this, the rising focus on improving respiratory care solutions is contributing to the growth of the market. In addition, increasing incidences of respiratory disorders among individuals are propelling the growth of the market.

Competitive Landscape:

Various companies are investing in research and development (R&D) activities to create DDIs with enhanced features, such as improved dose counting, adherence monitoring, and real-time feedback mechanisms, to cater to the needs of patients and healthcare providers. Apart from this, companies are engaging in collaborations and partnerships to expand their technological capabilities and market reach. In line with this, they are providing more user-friendly and effective solutions for managing respiratory diseases. Besides this, major manufacturers are working on specialized inhaler solutions that are tailored to deliver complex biologics. Furthermore, companies are engaging in marketing and awareness campaigns to educate healthcare providers and patients about the advantages of digital dose inhalers over traditional ones.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

3M Company

AstraZeneca plc

GlaxoSmithKline plc

Glenmark Pharmaceuticals Limited

H&T Presspart Manufacturing Ltd.

Koninklijke Philips N.V.

Lupin Limited

Novartis AG

OPKO Health Inc.

Propeller Health (ResMed)

Sensirion AG Switzerland

Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1. What was the size of the global digital dose inhaler market in 2024?
• 2. What is the expected growth rate of the global digital dose inhaler market during 2025-2033?
• 3. What are the key factors driving the global digital dose inhaler market?
• 4. What has been the impact of COVID-19 on the global digital dose inhaler market?
• 5. What is the breakup of the global digital dose inhaler market based on the type?
• 6. What is the breakup of the global digital dose inhaler market based on the product?
• 7. What are the key regions in the global digital dose inhaler market?
• 8. Who are the key players/companies in the global digital dose inhaler market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Digital Dose Inhaler Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Branded Medication
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Generics Medication
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Product

• 7.1 Metered Dose Inhaler
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Dry Powder Inhaler
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 3M Company
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 AstraZeneca plc
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 GlaxoSmithKline plc
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
  • 13.3.4 Glenmark Pharmaceuticals Limited
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 H&T Presspart Manufacturing Ltd.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 Koninklijke Philips N.V.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Lupin Limited
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 Novartis AG
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 OPKO Health Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
  • 13.3.10 Propeller Health (ResMed)
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
  • 13.3.11 Sensirion AG Switzerland
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
  • 13.3.12 Teva Pharmaceutical Industries Ltd.
    • 13.3.12.1 Company Overview
    • 13.3.12.2 Product Portfolio
    • 13.3.12.3 Financials